PharmaNews.eu
Thursday, 01 March 2012    PDF Print E-mail
Shire receives prestigious EURORDIS Company Award for exemplary work in rare diseases
ShireShire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that it has received the prestigious Company Award from the European Organisation for Rare Diseases (EURORDIS) for its exemplary work in the field of rare diseases. The EURORDIS Company Award, presented last night at the First International Rare Disease Day Gala Dinner in Brussels, is designed to reward outstanding accomplishments of pioneering companies developing treatments for rare disease.
Read more...
 
Wednesday, 30 May 2012    PDF Print E-mail
Jentadueto® (linagliptin/metformin hydrochloride) tablets recommended for approval
Eli Lilly and CompanyBoehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced they have received a positive opinion from the European Medicines Agency's (EMA) medicinal committee recommending approval of Jentadueto® (linagliptin/metformin hydrochloride) tablets, a medicine combining the DPP-4 inhibitor, linagliptin (the active ingredient in Tradjenta® tablets, marketed under the trade name Trajenta® in Europe) and metformin in a single tablet taken twice daily.
Read more...
 
Thursday, 20 September 2012    PDF Print E-mail
Lundbeck files for regulatory approval of the novel multimodal antidepressant, vortioxetine
LundbeckH. Lundbeck A/S (Lundbeck) today announced the submission to the European Medicines Agency (EMA) of a marketing authorisation application (MAA) for the approval of the investigational multimodal antidepressant vortioxetine (Lu AA21004), and the dossier has been accepted for review. Vortioxetine belongs to a new generation of antidepressants that has been developed for the treatment of patients with major depressive episodes (MDE).
Read more...
 
Friday, 14 September 2012    PDF Print E-mail
In line with its strategy, UCB expands its biotechnology base in Belgium
UCBIn line with its strategy, and in preparation for the growing demand for biological medicines, UCB today inaugurated its new pilot biotechnology plant at its Braine-L’Alleud site in Belgium. UCB's new biologics pilot production facility was officially opened at a ceremony attended by Jean-Claude Marcourt, Vice President and Minister for the Economy of the Walloon Government and Roch Doliveux, UCB's CEO.
Read more...
 
Tuesday, 27 November 2012    PDF Print E-mail
Abbott's HUMIRA® (Adalimumab) approved for severe active pediatric Crohn's disease
AbbottAbbott announced today that the European Commission has approved HUMIRA® (adalimumab) for the treatment of pediatric patients aged 6 to 17 years with severe active Crohn's disease (CD) who failed, are intolerant to, or have contraindications to conventional therapy. With this approval, HUMIRA becomes the first biologic treatment approved for these patients in more than five years. Pediatric CD is a chronic, debilitating condition of the gastrointestinal (GI) tract that affects up to 200,000 children worldwide.
Read more...
 


Page 7 of 303